Evidence map›Paper›PMID 37790943›Full record

ArticleFrontiers in immunology2023

Function-structure approach reveals novel insights on the interplay of Immunoglobulin G 1 proteoforms and Fc gamma receptor IIa allotypes.

Steffen Lippold, Karishma Mistry, Sunidhi Lenka, Kevin Whang, Peilu Liu, Sebastian Pitschi, Felix Kuhne, Dietmar Reusch, Lance Cadang, Alexander Knaupp and 4 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Steffen LippoldProtein Analytical Chemistry, Genentech, A Member of the Roche Group, South San Francisco, CA, United States.
Karishma MistryBiological Technologies, Genentech, A Member of the Roche Group, South San Francisco, CA, United States.
Sunidhi LenkaPharmaceutical Development, Genentech, A Member of The Roche Group, South San Francisco, CA, United States.
Kevin WhangBiological Technologies, Genentech, A Member of the Roche Group, South San Francisco, CA, United States.
Peilu LiuProtein Analytical Chemistry, Genentech, A Member of the Roche Group, South San Francisco, CA, United States.
Sebastian PitschiPharma Technical Development Europe, Roche Diagnostics GmbH, Penzberg, Germany.
Felix KuhnePharma Technical Development Europe, Roche Diagnostics GmbH, Penzberg, Germany.
Dietmar ReuschPharma Technical Development Europe, Roche Diagnostics GmbH, Penzberg, Germany.
Lance CadangProtein Analytical Chemistry, Genentech, A Member of the Roche Group, South San Francisco, CA, United States.
Alexander KnauppPharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.
Saeed IzadiPharmaceutical Development, Genentech, A Member of The Roche Group, South San Francisco, CA, United States.
Alexis DunkleBiological Technologies, Genentech, A Member of the Roche Group, South San Francisco, CA, United States.
Feng YangProtein Analytical Chemistry, Genentech, A Member of the Roche Group, South San Francisco, CA, United States.
Tilman SchlothauerPharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.
Roche (United States) · USRoche Pharma AG (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human Fc gamma receptor IIa (FcγRIIa) or CD32a has two major allotypes with a single amino acid difference at position 131 (histidine or arginine). Differences in FcγRIIa allotypes are known to impact immunological responses such as the clinical outcome of therapeutic monoclonal antibodies (mAbs). FcγRIIa is involved in antibody-dependent cellular phagocytosis (ADCP), which is an important contributor to the mechanism-of-action of mAbs by driving phagocytic clearance of cancer cells. Hence, understanding the impact of individual mAb proteoforms on the binding to FcγRIIa, and its different allotypes, is crucial for defining meaningful critical quality attributes (CQAs). Here, we report a function-structure based approach guided by novel FcγRIIa affinity chromatography-mass spectrometry (AC-MS) assays to assess individual IgG1 proteoforms. This allowed to unravel allotype-specific differences of IgG1 proteoforms on FcγRIIa binding. FcγRIIa AC-MS confirmed and refined structure-function relationships of IgG1 glycoform interactions. For example, the positive impact of afucosylation was higher than galactosylation for FcγRIIa Arg compared to FcγRIIa His. Moreover, we observed FcγRIIa allotype-opposing and IgG1 proteoform integrity-dependent differences in the binding response of stress-induced IgG1 proteoforms comprising asparagine 325 deamidation. The FcγRIIa-allotype dependent binding differences resolved by AC-MS were in line with functional ADCP-surrogate bioassay models. The molecular basis of the observed allotype specificity and proteoform selectivity upon asparagine 325 deamidation was elucidated using molecular dynamics. The observed differences were attributed to the contributions of an inter-molecular salt bridge between IgG1 and FcγRIIa Arg and the contribution of an intra-molecular hydrophobic pocket in IgG1. Our work highlights the unprecedented structural and functional resolution of AC-MS approaches along with predictive biological significance of observed affinity differences within relevant cell-based methods. This makes FcγRIIa AC-MS an invaluable tool to streamline the CQA assessment of therapeutic mAbs.

Indexed as

AsparagineImmunoglobulin GAntibodies, MonoclonalHumansPhagocytosisReceptors, IgGAntibodies, MonoclonalAsparagineFc gamma receptor IIAImmunoglobulin GReceptors, IgGADCPaffinity chromatograghyCD32 (FcgRII)critical quality attribute (CQA)deamidationglycosylationmass spectrometrymolecular dynamics

Identifiers

PMID37790943
PMCPMC10544997
OpenAlexW4386864248

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.